The GRK2/PI3K/AKT signaling axis, along with p53 transactivation‐independent activities, contributes to the robustness of G2 checkpoint and survival, suggesting potential implications for the chemotherapeutic response of wild-type p53 retaining tumor cells. The gene discussed is TP53; the disease is neoplasm.